ASPRE (Version 1)
Research type
Research Study
Full title
Combined Multi-Marker Screening and Randomised Patient Treatment with Aspirin for Evidence-based Pre-eclampsia Prevention
IRAS ID
128168
Contact name
Kypros Nicolaides
Contact email
Sponsor organisation
University College London
Eudract number
2013-003778-29
ISRCTN Number
ISRCTN13633058
Research summary
The placenta (afterbirth) is responsible for providing food and oxygen to the baby. When there is a problem with the function of the placenta the baby may not grow well and the mother can develop high blood pressure (pre-eclampsia).
Placental problems affect about 10% of pregnancies. The consequences are usually minor but occasionally they can be serious both for the mother and the baby.
The flow of blood through the uterine arteries (blood vessels which supply blood to the placenta), maternal blood pressure and the amount of proteins produced by the placenta in the mother’s blood are important in determining whether she is at increased risk of developing preeclampsia or problems with the growth of the baby.
Some studies have shown that low-dose of aspirin started at 16 weeks or earlier may reduce the chance of developing pre-eclampsia. However, the small number and small size of individual trials preclude definitive conclusions to be drawn regarding the effectiveness of aspirin starting before 16 weeks and the results need to be examined in a prospective major randomised trial.
The aim of our study is to see whether low dose aspirin can reduce these complications in women at high risk of developing high blood pressure during pregnancy.REC name
London - Fulham Research Ethics Committee
REC reference
13/LO/1479
Date of REC Opinion
12 Nov 2013
REC opinion
Further Information Favourable Opinion